Owning big pharma stocks in recent years has pretty much been a prescription for losing money. Product recalls (Vioxx and Bextra, for example), litigation, patent expirations, generic competition, limp new-drug pipelines and unfavorable publicity have buffeted the sector. Stocks such as Pfizer and Eli Lilly have been mostly falling since early 2004.
But over in Europe, pharmaceutical stocks such as Novartis and Roche have been in ruddy good health. Wendell Perkins, co-manager of JohnsonFamily International Value, recommends Sanofi-Aventis, a French pharma giant formed in a 2004 megamerger. Perkins favors Aventis, the world's third largest drugmaker (after Pfizer and GlaxoSmithKline), for its deep, diverse product portfolio and promising pipeline.
Consider: Aventis boasts billion-dollar blockbuster drugs in categories ranging from anti-coagulants (Lovenox and Plavix) and oncology medicines (Taxotene and Eloxatin) to diabetes (Lantus) and insomnia (Ambien) fighters. The company also sells the leading vaccines for afflictions such as influenza and polio. The sources of Aventis's revenues are well balanced geographically: Europe accounts for 40% of sales, the U.S. for 30%, and the rest of the world the remaining 30%.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Aventis's laboratories have been remarkably fertile. They are currently developing 129 products. Perkins thinks Acomplia, an anti-obesity drug expected to receive approval from the Food and Drug Administration in the second half of this year, will be a new blockbuster.
Sanofi-Aventis is still benefiting from large cost savings wrung out of the merged companies. But unlike many U.S. drug companies, sales growth -- 10% in the first quarter of this year -- has remained robust. Trading at $48 a share, Aventis's American depositary receipts (symbol SNY) sell for 14 times the average of analysts' 2006 earnings estimates.
--Andrew Tanzer
-
Stocks Chop as the Unemployment Rate Jumps: Stock Market TodayNovember job growth was stronger than expected, but sharp losses in October and a rising unemployment rate are worrying market participants.
-
Should You Renew Your CD?With rate cuts impacting earnings, we examine if now is a wise time to renew CDs.
-
7 Ways to Plan Now to Save on Medicare IRMAA Surcharges LaterUnderstand the critical two-year lookback period and why aggressive planning before you enroll in Medicare is the most effective way to minimize IRMAA.
-
If You'd Put $1,000 Into Coca-Cola Stock 20 Years Ago, Here's What You'd Have TodayEven with its reliable dividend growth and generous stock buybacks, Coca-Cola has underperformed the broad market in the long term.
-
If You Put $1,000 into Qualcomm Stock 20 Years Ago, Here's What You Would Have TodayQualcomm stock has been a big disappointment for truly long-term investors.
-
If You'd Put $1,000 Into Home Depot Stock 20 Years Ago, Here's What You'd Have TodayHome Depot stock has been a buy-and-hold banger for truly long-term investors.
-
What the Rich Know About Investing That You Don'tPeople like Warren Buffett become people like Warren Buffett by following basic rules and being disciplined. Here's how to accumulate real wealth.
-
If You'd Put $1,000 Into Bank of America Stock 20 Years Ago, Here's What You'd Have TodayBank of America stock has been a massive buy-and-hold bust.
-
If You'd Put $1,000 Into Oracle Stock 20 Years Ago, Here's What You'd Have TodayORCL Oracle stock has been an outstanding buy-and-hold bet for decades.
-
How to Invest for Rising Data Integrity RiskAmid a broad assault on venerable institutions, President Trump has targeted agencies responsible for data critical to markets. How should investors respond?
-
If You'd Put $1,000 Into Sherwin-Williams Stock 20 Years Ago, Here's What You'd Have TodaySherwin-Williams stock has clobbered the broader market by a wide margin for a long time.
